Moderna’s stock jumps 6% as its cancer vaccine could treat more than just melanoma
Moderna’s stock got a boost on Tuesday after positive data was released from a trial of a form of head-and-neck cancer.
Moderna’s stock got a boost on Tuesday after positive data was released from a trial of a form of head-and-neck cancer.